These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22474725)

  • 41. Tacalcitol and narrow-band phototherapy in patients with vitiligo.
    Leone G; Pacifico A; Iacovelli P; Paro Vidolin A; Picardo M
    Clin Exp Dermatol; 2006 Mar; 31(2):200-5. PubMed ID: 16487090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depigmentation Therapies for Vitiligo.
    Grimes PE; Nashawati R
    Dermatol Clin; 2017 Apr; 35(2):219-227. PubMed ID: 28317530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Depigmentation during vitiligo activity spares epithelial grafted areas.
    Awad SS
    J Cosmet Dermatol; 2016 Dec; 15(4):383-386. PubMed ID: 27369365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effectiveness of topical therapy combined with 308-nm excimer laser on vitiligo compared to excimer laser monotherapy in pediatric patients.
    Li L; Liang Y; Hong J; Lan L; Xiao H; Xie Z
    Pediatr Dermatol; 2019 Jan; 36(1):e53-e55. PubMed ID: 30520111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beyond Traditional Treatment: The Importance of Psychosocial Therapy in Vitiligo.
    Rzepecki AK; McLellan BN; Elbuluk N
    J Drugs Dermatol; 2018 Jun; 17(6):688-691. PubMed ID: 29879259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repigmentation by combined narrow‑band ultraviolet B/adipose‑derived stem cell transplantation in the mouse model: Role of Nrf2/HO‑1‑mediated Ca
    Bian Y; Yu H; Jin M; Gao X
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34751412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different treatment modalities in 149 patients.
    Buggiani G; Tsampau D; Hercogovà J; Rossi R; Brazzini B; Lotti T
    Dermatol Ther; 2012; 25(5):472-6. PubMed ID: 23046028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dihydroxyacetone: a safe camouflaging option in vitiligo.
    Rajatanavin N; Suwanachote S; Kulkollakarn S
    Int J Dermatol; 2008 Apr; 47(4):402-6. PubMed ID: 18377610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin.
    Harris JE; Harris TH; Weninger W; Wherry EJ; Hunter CA; Turka LA
    J Invest Dermatol; 2012 Jul; 132(7):1869-76. PubMed ID: 22297636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelet-rich plasma: Potential role in combined therapy for vitiligo.
    Shih S
    Dermatol Ther; 2019 Jan; 32(1):e12773. PubMed ID: 30338878
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of Ultraviolet Light on Vitiligo.
    Singh RK
    Adv Exp Med Biol; 2017; 996():55-60. PubMed ID: 29124690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Translational Research in Vitiligo.
    Katz EL; Harris JE
    Front Immunol; 2021; 12():624517. PubMed ID: 33737930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Koebner's phenomenon induced vitiligo following Nd:YAG laser epilation treatment in a woman with a past history of a Sutton nevus.
    Mavilia L; Mercuri SR
    Dermatol Ther; 2014; 27(6):355-6. PubMed ID: 25056010
    [No Abstract]   [Full Text] [Related]  

  • 54. Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis.
    Kim YJ; Chung BS; Choi KC
    Dermatol Surg; 2001 Nov; 27(11):969-70. PubMed ID: 11737134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vitiligo.
    Picardo M; Dell'Anna ML; Ezzedine K; Hamzavi I; Harris JE; Parsad D; Taieb A
    Nat Rev Dis Primers; 2015 Jun; 1():15011. PubMed ID: 27189851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Skin bleaching: highlighting the misuse of cutaneous depigmenting agents.
    Dadzie OE; Petit A
    J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):741-50. PubMed ID: 19470077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repigmentation of acrofacial vitiligo with subcutaneous tildrakizumab.
    Jerjen R; Moodley A; Sinclair R
    Australas J Dermatol; 2020 Nov; 61(4):e446-e448. PubMed ID: 32441048
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical repigmentation patterns in paediatric vitiligo.
    Gan EY; Gahat T; Cario-André M; Seneschal J; Ezzedine K; Taïeb A
    Br J Dermatol; 2016 Sep; 175(3):555-60. PubMed ID: 27037527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic options and hot topics in vitiligo with special focus on pediatrics' vitiligo: A comprehensive review study.
    Roohaninasab M; Mansouri P; Seirafianpour F; Naeini AJ; Goodarzi A
    Dermatol Ther; 2021 Jan; 34(1):e14550. PubMed ID: 33200859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of using fractional CO
    Ghasemloo S; Gauthier Y; Ghalamkarpour F
    J Dermatolog Treat; 2019 Nov; 30(7):697-700. PubMed ID: 30592235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.